Eisai reports Phase Ib/II data for Lenvima plus Keytruda in RCC

In September, Eisai Co. Ltd. (Tokyo:4523) reported data from a cohort of 30 patients with metastatic renal cell carcinoma (RCC) in the Phase II portion of the Phase Ib/II Study 111 showing

Read the full 328 word article

User Sign In